



**CURRENT CLINICAL FINDINGS ON THE THERAPEUTIC USE OF
CONCENTRATED BONE MARROW-DERIVED STEM CELLS WILL BE
PRESENTED DURING THERMOGENESIS SYMPOSIUM AT LEADING CELLULAR
THERAPY MEETING IN EUROPE**

(RANCHO CORDOVA, CA), SEPTEMBER 8, 2010—ThermoGenesis Corp. (NASDAQ: KOOLD), a leading supplier of innovative products and services that process and store adult stem cells, said today that findings from the use of concentrated bone marrow-derived stem cells in orthopedic and Critical Limb Ischemia (CLI) applications will be presented at the upcoming International Stem Cell Therapy (ISCT)-Europe regional meeting in Belgirate, Italy.

The symposium, which takes place on Sunday, September 12, is titled “The Role of Cell Therapy in Limb Salvage and Spinal Fusion: A Multicenter Experience with Bone Marrow Derived Mononuclear Cells in Clinical Practice.”

At the symposium, ThermoGenesis will be displaying its offerings serving the bone marrow stem cell market—the Res-Q™ 60 BMC (Res-Q) and MXP™ MarrowXpress™ (MXP) Systems. The Company will also be exhibiting its AXP® AutoXpress™ (AXP) and BioArchive Systems, which are used for the processing and storage of stem cells from cord blood.

The ISCT is a global forum and resource for developing and supporting innovative therapies through communication, education and training, furthering clinical-based investigation for the benefit of patients that attracts international experts in the field of cellular therapy.

The symposium will feature presentations by Dr. James Poser, Executive Vice President of Regenerative Medicine of Celling Technologies, and Dr. Gilda Cobellis of the Seconda Universta'd Napoli, in Naples Italy.

Dr. Poser will describe the clinical outcomes achieved using adult stem cells produced at the point-of-care using the Res-Q System to prepare concentrates from bone marrow aspirates. Celling Technologies is a distributor of the Res-Q and MXP Systems in the U.S.

Dr. Cobellis will discuss the use of adult stem cells derived using the MXP System with CLI patients as part of the phase II clinical trial being conducted in Italy. Initial results of the phase I trial reported earlier this year demonstrated increased perfusion in treated limbs, which is an important measure of blood circulation.

“We are looking forward to this symposium and the sharing of the data from these presentations with ISCT attendees and the value of the data from this event to increase awareness about our compelling technology among leaders in regenerative medicine,” said J. Melville Engle, Chief Executive Officer of ThermoGenesis.

About ThermoGenesis Corp.

ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These include:

- The BioArchive[®] System, an automated cryogenic device, is used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.
- AXP[®] AutoXpress[™] Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP[™] MarrowXpress[™] and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. The MXP is used for the preparation of cell concentrates, including stem cells, from bone marrow aspirates in the laboratory setting.
- The Res-Q[™] 60 BMC (Res-Q), a point-of-care system that is designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates.
- The CryoSeal[®] FS System, an automated device and companion sterile blood processing disposable, is used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community.

This press release contains forward-looking statements, and such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal years 2010 and 2011, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2010 and 2011. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

ThermoGenesis Corp.

Web site: <http://www.thermogenesis.com>

Contact: Investor Relations

+1-916-858-5107, or

ir@thermogenesis.com